Elevation Oncology, Inc. (ELEV)

NASDAQ: ELEV · Delayed Price · USD
6.00
0.00 (0.00%)
At close: Jan 18, 2022 12:00 AM
6.10
0.10 (1.67%)
After-hours:Jan 18, 2022 4:00 PM EST
Market Cap139.35M
Revenue (ttm)n/a
Net Income (ttm)-31.31M
Shares Out23.23M
EPS (ttm)-4.82
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume33
Open6.26
Previous Close6.00
Day's Range5.85 - 6.26
52-Week Range4.15 - 16.22
Betan/a
AnalystsStrong Buy
Price Target20.00 (+233.3%)
Earnings DateNov 11, 2021

About ELEV

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York.

IndustryBiotechnology
IPO DateJun 25, 2021
Employees17
Stock ExchangeNASDAQ
Ticker SymbolELEV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ELEV stock is "Strong Buy." The 12-month stock price forecast is 20.00, which is an increase of 233.33% from the latest price.

Price Target
$20.00
(233.33% upside)
Analyst Consensus: Strong Buy

News

Elevation Oncology Highlights 2021 Achievements and Outlines Expected 2022 Milestones

NEW YORK, Jan. 10, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...

1 week ago - PRNewsWire

Elevation Oncology to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically...

1 week ago - PRNewsWire

Elevation Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 5, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically...

2 weeks ago - PRNewsWire

Elevation Oncology to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

NEW YORK, Nov. 18, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...

2 months ago - PRNewsWire

Elevation Oncology Reports Third Quarter 2021 Financial Results

NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...

2 months ago - PRNewsWire

Elevation Oncology Announces the Promotion of Valerie Malyvanh Jansen, M.D., Ph.D., to Chief Medical Officer

NEW YORK, Oct. 20, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...

2 months ago - PRNewsWire

Elevation Oncology's Seribantumab Included as Part of a Case Series Presentation at the Australasian Gastro-Intestina...

NEW YORK, Oct. 14, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...

3 months ago - PRNewsWire

Elevation Oncology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

NEW YORK, Sept. 7, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...

4 months ago - PRNewsWire

Elevation Oncology Reports Second Quarter 2021 Financial Results

NEW YORK, Aug. 12, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...

5 months ago - PRNewsWire

Elevation Oncology to Present at the 12th Annual Wedbush PacGrow Healthcare Conference

NEW YORK, Aug. 4, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically...

5 months ago - PRNewsWire

Elevation Oncology Announces Pricing of Initial Public Offering

NEW YORK, June 24, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...

6 months ago - PRNewsWire